Similar articles

• P2Y₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary intervention.

  Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O'Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. Capodanno D, et al. Nat Rev Cardiol. 2022 Dec;19(12):829-844. doi: 10.1038/s41569-022-00725-6. Epub 2022 Jun 13. Nat Rev Cardiol. 2022. PMID: 35697777 Review.
• MASTER-DAPT: A Further Step Toward Long-Term P2Y₁₂ Blocker Monotherapy After PCI.

  Verheugt FWA. Verheugt FWA. JACC Cardiovasc Interv. 2023 Apr 10;16(7):813-815. doi: 10.1016/j.jcin.2023.02.016. JACC Cardiovasc Interv. 2023. PMID: 37045501 No abstract available.
• Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.

  Shin ES, Her AY, Kim B, Hahn JY, Song YB, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Shin ES, et al. J Korean Med Sci. 2023 Nov 20;38(45):e383. doi: 10.3346/jkms.2023.38.e383. J Korean Med Sci. 2023. PMID: 37987108 Free PMC article. Clinical Trial.
• Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.

  Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Hahn JY, et al. JAMA. 2019 Jun 25;321(24):2428-2437. doi: 10.1001/jama.2019.8146. JAMA. 2019. PMID: 31237645 Free PMC article. Clinical Trial.
• Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.

  Wu XT, He RR, Liang SZ, Ye GY, Ding SB. Wu XT, et al. Minerva Med. 2020 Apr;111(2):173-180. doi: 10.23736/S0026-4806.19.06281-5. Minerva Med. 2020. PMID: 32338843